Type 2 diabetes is a chronic metabolic disorder characterized by high blood sugar levels resulting from insulin resistance or the body's inability to produce enough insulin.
Insulin is a hormone produced by the pancreas that regulates the body's use of glucose for energy. Type 2 diabetes is the most common form of diabetes, accounting for approximately 90-95% of all diabetes cases.
The exact cause of type 2 diabetes is not yet fully understood, but it is known that several risk factors can increase a person's likelihood of developing the disease. These risk factors include obesity, sedentary lifestyle, and family history of diabetes, age, and ethnicity.
The symptoms of type 2 diabetes can be mild or non-existent in the early stages of the disease. However, as the disease progresses, symptoms can become more severe.
Symptoms of type 2 diabetes include frequent urination, excessive thirst, hunger, fatigue, blurry vision, and slow-healing wounds or infections.
Diagnosis of type 2 diabetes is typically done through blood tests, including a fasting plasma glucose test or an A1C test.
Treatment of type 2 diabetes typically involves lifestyle changes, such as diet and exercise, and medication to manage blood sugar levels.
Type 2 diabetes is a chronic metabolic disorder characterized by high blood sugar levels resulting from insulin resistance or the body's inability to produce enough insulin. Risk factors for type 2 diabetes include obesity, sedentary lifestyle, and family history of diabetes, age, and ethnicity. Symptoms of type 2 diabetes can be mild or non-existent in the early stages of the disease. Treatment of type 2 diabetes typically involves lifestyle changes, such as diet and exercise, and medication to manage blood sugar levels. With proper management, people with type 2 diabetes can lead healthy and active lives.
Stem cell therapy is an emerging area of research for the treatment of type 2 diabetes, a chronic metabolic disorder characterized by high blood sugar levels resulting from insulin resistance or the body's inability to produce enough insulin.
Stem cells are undifferentiated cells that have the ability to differentiate into various cell types in the body, including insulin-producing beta cells in the pancreas. One of the major challenges in the treatment of type 2 diabetes is the loss of insulin-producing beta cells in the pancreas.
Stem cell therapy aims to restore the function of these cells and improve insulin sensitivity in the body. There are several types of stem cells that have been studied for the treatment of type 2 diabetes, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells.
Embryonic Stem Cells: Embryonic stem cells are derived from early-stage embryos and have the potential to differentiate into any cell type in the body. However, the use of embryonic stem cells is controversial due to ethical concerns, and their use is heavily regulated in many countries.
Induced Pluripotent Stem Cells: Induced pluripotent stem cells (IPSCs) are derived from adult cells that have been reprogrammed to a pluripotent state. This technology allows for the generation of patient-specific stem cells, which can be used for personalized treatments. IPSCs have been shown to differentiate into insulin-producing beta cells in vitro, and studies have demonstrated their potential for the treatment of type 2 diabetes.
Adult Stem Cells: Adult stem cells, also known as tissue-specific stem cells, are found in various tissues in the body, including the bone marrow, adipose tissue, and pancreas. Adult stem cells have the ability to differentiate into certain cell types in their respective tissues. Studies have shown that adult stem cells from the bone marrow and adipose tissue can differentiate into insulin-producing beta cells in vitro and improve insulin sensitivity in animal models of type 2 diabetes.
Several clinical trials have been conducted to investigate the safety and efficacy of stem cell therapy for the treatment of type 2 diabetes.
While the results of these clinical trials are promising, further research is needed to determine the long-term safety and efficacy of stem cell therapy for the treatment of type 2 diabetes. There are also several challenges associated with stem cell therapy, including the risk of immune rejection, the potential for the formation of tumours, and the difficulty of controlling the differentiation of stem cells into specific cell types.
In conclusion, stem cell therapy is an emerging area of research for the treatment of type 2 diabetes. Stem cells have the potential to differentiate into insulin-producing beta cells and improve insulin sensitivity in the body. Several types of stem cells, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, have been studied for the treatment of type 2 diabetes. Clinical trials have shown promising results, but further research is needed to determine the long-term safety and efficacy of stem cell therapy for the treatment of type 2 diabetes.
In our centre, we prefer to put stem cells directly into the pancreas through femoral artery in a catheterisation laboratory. This approach implants 98% cells into the pancreas compared to just 2% by giving into a vein, as done by other centres. This therapy is called intrapancreatic stem cell therapy which was done by us for the first time in the world. Currently, our centre is the only centre which offers this therapy.